Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Inclusion Criteria: * Histologically proven ovarian cancer with evidence of recurrence or progression * Failed first-line platinum containing therapy after 6 months of treatment discontinuation * Documented lesion as evidenced by appropriate computerized tomography (CT), magnetic resonance imaging (MRI) scan, chest x-ray, or ultrasound. * Previous hormonal therapy or radiotherapy must be terminated at least 3 weeks before study drug administration * Adequate bone marrow reserve: neutrophils ≥ 1.5 x 10\^9/L and platelets ≥ 100 x 10\^9/L Exclusion Criteria: * Receiving concomitant cytotoxic or other antineoplastic treatment. Hormone replacement therapy is allowed, as are steroid antiemetics * Clinical evidence of central nervous system metastases * Active infection * Cannot adequately be followed up for the duration of the study * A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) * Use of any investigational agent in the 3 weeks prior to inclusion * Serious concomitant systematic disorders incompatible with the study * Received more than one previous chemotherapy regimen or had prior gemcitabine treatment * Patients with tumor of borderline malignancy * Patients with estimated GFR ≤ 50 mL/min